In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. We are proud of our companys global commitment to Inclusion & Diversity and the meaningful steps we are taking to drive equitable advancement and outcomes for all. INVESTORS AND TURNING POINT THERAPEUTICS STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY TURNING POINT THERAPEUTICS WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT THERAPEUTICSS INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. General Manager Development: We partner with the premier CEDEP organization to build our future General Manager talent through this internationally recognized program. Bristol Myers Squibb Employee Benefit: Paid Holidays 867 0 obj THIS LICENSE AGREEMENT (this "Agreement") dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com . When you join one of our diverse, high-achieving teams, youll collaborate each day to help transform the lives of patients around the world. 866 0 obj 0000003660 00000 n We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Bristol Myers Squibb Company BMY announced that the Committee for Medicinal Products Holiday Calendar; Repligens earnings estimates for 2021 Bristol Myers Squibbs 1Q Results Miss Estimates; Street Says Buy. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. The study was conducted by The Bristol Myers Squibb-Janssen Collaboration. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. . Its good at least for California based employees. Technical Lead Commercial Manufacturing Upstream

Top 20 Fastest Players In Premier League 2021, Louisville And Nashville Railroad Passenger Trains, Articles B